In This Issue/Research Watch/News-in-Brief/News from the IASLC Tobacco Control Committee

Abstract

(>1%), advanced NSCLC. Lack of efficacy after treating 11 of 25 planned patients led to termination of study enrollment. The treatment naïve group accounted for 82% of trial patients, 64% had sensitizing EGFR mutations, and 73% had PD-L1 expression >50%. The objective response found in one patient (ORR ¼ 9%) was later confirmed to be independent of EGFR mutation. No new drug-related adverse events with pembrolizumab, while 2 deaths within 6 months of enrollment were of concern. Taken together, the authors concluded that pembrolizumab is not appropriate for the treatment of patients with advanced NSCLC, who are TKI naive, EGFR-mutation positive, and PD-L1 positive. (p.